Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism.

Honkanen EA, Kemppainen N, Noponen T, Seppänen M, Joutsa J, Kaasinen V.

Clin Neuropharmacol. 2019 Sep/Oct;42(5):181-183. doi: 10.1097/WNF.0000000000000359.

PMID:
31361666
2.

Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).

Stephen R, Liu Y, Ngandu T, Antikainen R, Hulkkonen J, Koikkalainen J, Kemppainen N, Lötjönen J, Levälahti E, Parkkola R, Pippola P, Rinne J, Strandberg T, Tuomilehto J, Vanninen R, Kivipelto M, Soininen H, Solomon A; FINGER study group.

Alzheimers Res Ther. 2019 Jun 4;11(1):53. doi: 10.1186/s13195-019-0506-z.

3.

Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline.

Martikainen IK, Kemppainen N, Johansson J, Teuho J, Helin S, Liu Y, Helisalmi S, Soininen H, Parkkola R, Ngandu T, Kivipelto M, Rinne JO.

AJNR Am J Neuroradiol. 2019 Jan;40(1):80-85. doi: 10.3174/ajnr.A5891. Epub 2018 Dec 13.

PMID:
30545837
4.

Brain amyloid load and its associations with cognition and vascular risk factors in FINGER Study.

Kemppainen N, Johansson J, Teuho J, Parkkola R, Joutsa J, Ngandu T, Solomon A, Stephen R, Liu Y, Hänninen T, Paajanen T, Laatikainen T, Soininen H, Jula A, Rokka J, Rissanen E, Vahlberg T, Peltoniemi J, Kivipelto M, Rinne JO.

Neurology. 2018 Jan 16;90(3):e206-e213. doi: 10.1212/WNL.0000000000004827. Epub 2017 Dec 20.

PMID:
29263220
5.

Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition.

Stephen R, Liu Y, Ngandu T, Rinne JO, Kemppainen N, Parkkola R, Laatikainen T, Paajanen T, Hänninen T, Strandberg T, Antikainen R, Tuomilehto J, Keinänen Kiukaanniemi S, Vanninen R, Helisalmi S, Levälahti E, Kivipelto M, Soininen H, Solomon A.

J Alzheimers Dis. 2017;59(2):695-705. doi: 10.3233/JAD-170092.

6.

Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.

Kemppainen N, Joutsa J, Johansson J, Scheinin NM, Någren K, Rokka J, Parkkola R, Rinne JO.

J Alzheimers Dis. 2015;48(1):123-33. doi: 10.3233/JAD-150190.

PMID:
26401934
7.

Effect of inherent misalignment and head motion in neurological PET/MR with the Philips Ingenuity TF - phantom and patient study.

Teuho J, Johansson J, Saunavaara V, Kemppainen N, Teräs M.

EJNMMI Phys. 2014 Jul;1(Suppl 1):A65. doi: 10.1186/2197-7364-1-S1-A65. No abstract available.

8.

Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.

Kemppainen NM, Scheinin NM, Koivunen J, Johansson J, Toivonen JT, Någren K, Rokka J, Karrasch M, Parkkola R, Rinne JO.

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):283-9. doi: 10.1007/s00259-013-2562-0. Epub 2013 Sep 27.

PMID:
24072346
9.

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K, Helin S, Scheinin M, Rinne JO.

Neurology. 2009 Oct 13;73(15):1186-92. doi: 10.1212/WNL.0b013e3181bacf1b. Epub 2009 Sep 2.

PMID:
19726751
10.

Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.

Aalto S, Scheinin NM, Kemppainen NM, Någren K, Kailajärvi M, Leinonen M, Scheinin M, Rinne JO.

Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1651-60. doi: 10.1007/s00259-009-1174-1. Epub 2009 Jun 4.

PMID:
19495749
11.

In vivo mapping of amyloid toxicity in Alzheimer disease.

Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Någren K, Rinne JO.

Neurology. 2009 Apr 28;72(17):1504-11. doi: 10.1212/WNL.0b013e3181a2e896.

PMID:
19398705
12.

Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation.

Tenovuo O, Kemppainen N, Aalto S, Någren K, Rinne JO.

J Alzheimers Dis. 2008 Nov;15(3):351-5.

PMID:
18997288
13.

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.

Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Någren K, Rinne JO, Soininen H.

Dement Geriatr Cogn Disord. 2008;26(4):378-83. doi: 10.1159/000163927. Epub 2008 Oct 16.

PMID:
18931497
14.

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ.

J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1331-8. doi: 10.1136/jnnp.2007.127878. Epub 2008 Jul 24.

PMID:
18653550
15.

Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2169-81. doi: 10.1007/s00259-008-0833-y. Epub 2008 Jun 20.

16.

Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication.

Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H, Någren K, Parkkola R, Rinne JO.

Arch Neurol. 2008 Apr;65(4):540-4. doi: 10.1001/archneur.65.4.540.

PMID:
18413480
17.

Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease.

Kemppainen NM, Aalto S, Karrasch M, Någren K, Savisto N, Oikonen V, Viitanen M, Parkkola R, Rinne JO.

Ann Neurol. 2008 Jan;63(1):112-8.

PMID:
18023012
18.

Brain white matter expansion in human obesity and the recovering effect of dieting.

Haltia LT, Viljanen A, Parkkola R, Kemppainen N, Rinne JO, Nuutila P, Kaasinen V.

J Clin Endocrinol Metab. 2007 Aug;92(8):3278-84. Epub 2007 May 29.

PMID:
17536002
19.

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2007 May 8;68(19):1603-6.

PMID:
17485647
20.

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2006 Nov 14;67(9):1575-80. Epub 2006 Sep 13.

PMID:
16971697
21.

Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease.

Kemppainen N, Laine M, Laakso MP, Kaasinen V, Någren K, Vahlberg T, Kurki T, Rinne JO.

Eur J Neurosci. 2003 Jul;18(1):149-54.

PMID:
12859348
22.

Age-related loss of extrastriatal dopamine D(2) -like receptors in women.

Kaasinen V, Kemppainen N, Någren K, Helenius H, Kurki T, Rinne JO.

J Neurochem. 2002 Jun;81(5):1005-10.

23.

Unbiased morphological measurements show no neuronal loss in the substantia nigra in Alzheimer's disease.

Kemppainen N, Röyttä M, Collan Y, Ma SY, Hinkka S, Rinne JO.

Acta Neuropathol. 2002 Jan;103(1):43-7.

PMID:
11837746
24.

Different pattern of reduction of striatal dopamine reuptake sites in Alzheimer's disease and ageing.

Kemppainen N, Marjamäki P, Röyttä M, Rinne JO.

J Neural Transm (Vienna). 2001;108(7):827-36.

PMID:
11515748
25.

PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.

Kemppainen N, Ruottinen H, Nâgren K, Rinne JO.

Neurology. 2000 Jul 25;55(2):205-9.

PMID:
10908891

Supplemental Content

Loading ...
Support Center